Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced that Aimmune Therapeutics, a Nestle Health Science Company, has selected it as a limited distribution partner for VOWST™ (fecal microbiota spores, live-brpk) to prevent the recurrence of C. difficile Infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI). For more information about VOWST, see the Full Prescribing Information.
CDI is a bacterium of the intestine that causes life-threatening diarrhea. Although CDI can affect anyone, people over 65 are most vulnerable to the infection. Recurrent CDI is a serious condition that afflicts a significant number of patients. CDI is considered recurrent when a patient experiences symptom onset and has a positive test in the 2–8-week period following the resolution of symptoms.
“We are honored to partner with Aimmune Therapeutics and add VOWST to our expanding portfolio of novel therapies,” said Brandon Tom, Orsini’s President and Chief Executive Officer. “Orsini Specialty Pharmacy’s dedicated Care Team will ensure patients receive VOWST as quickly as possible and provide compassion, care, and support to meet their individual needs.”
About Orsini Specialty Pharmacy
Providing patients with comprehensive and compassionate care since 1987, Orsini Specialty Pharmacy is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers, and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated pharmacy distribution, patient services, clinical management, and convenient home infusion services, Orsini delivers customized solutions that simplify how patients connect to advanced therapies. Orsini’s high-touch care model centers on experienced and trained therapy care teams that provide personalized patient care to ensure that No Patient is Left Behind™.
Orsini Specialty Pharmacy holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC, and NABP. Orsini has earned URAC’s Rare Disease Pharmacy Center of Excellence Designation and ACHC’s Distinction in Rare Diseases and Orphan Drugs. For more information about Orsini, visit www.orsini.com/.
Click here to discover how Orsini supports patients with rCDI.